Shopping Cart 0
Cart Subtotal
USD 0

Dermal Filler-Medical Devices Pipeline Assessment, 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 4000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 8000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 12000

Details

Dermal Filler-Medical Devices Pipeline Assessment, 2017

Summary

GlobalData's Medical Devices sector report, "Dermal Filler-Medical Devices Pipeline Assessment, 2017" provides an overview of Dermal Filler currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dermal Filler pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

Extensive coverage of the Dermal Filler under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Dermal Filler and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

Reasons to buy

The report enables you to-

Formulate significant competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Dermal Filler under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the product's current stage of development, territory and estimated launch date

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 8

2 Introduction 9

2.1 Dermal Filler Overview 9

3 Products under Development 10

3.1 Dermal Filler-Pipeline Products by Stage of Development 10

3.2 Dermal Filler-Pipeline Products by Territory 11

3.3 Dermal Filler-Pipeline Products by Regulatory Path 12

3.4 Dermal Filler-Pipeline Products by Estimated Approval Date 13

3.5 Dermal Filler-Ongoing Clinical Trials 14

4 Dermal Filler-Pipeline Products under Development by Companies 15

4.1 Dermal Filler Companies-Pipeline Products by Stage of Development 15

4.2 Dermal Filler-Pipeline Products by Stage of Development 17

5 Dermal Filler Companies and Product Overview 19

5.1 Aeon Astron Corporation Company Overview 19

5.1.1 Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 19

5.2 Allergan Inc Company Overview 20

5.2.1 Allergan Inc Pipeline Products & Ongoing Clinical Trials Overview 20

5.3 Almirall Ltd Company Overview 26

5.3.1 Almirall Ltd Pipeline Products & Ongoing Clinical Trials Overview 26

5.4 Anika Therapeutics Inc Company Overview 27

5.4.1 Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 27

5.5 BioPolymer GmbH & Co. KG Company Overview 28

5.5.1 BioPolymer GmbH & Co. KG Pipeline Products & Ongoing Clinical Trials Overview 28

5.6 Bioxis Pharmaceuticals Company Overview 30

5.6.1 Bioxis Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview 30

5.7 Cytophil, Inc. Company Overview 32

5.7.1 Cytophil, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32

5.8 Dermele Skin Care, LLC Company Overview 33

5.8.1 Dermele Skin Care, LLC Pipeline Products & Ongoing Clinical Trials Overview 33

5.9 EternoGen, LLC Company Overview 34

5.9.1 EternoGen, LLC Pipeline Products & Ongoing Clinical Trials Overview 34

5.10 FibroGen Inc Company Overview 35

5.10.1 FibroGen Inc Pipeline Products & Ongoing Clinical Trials Overview 35

5.11 Galderma SA Company Overview 36

5.11.1 Galderma SA Pipeline Products & Ongoing Clinical Trials Overview 36

5.12 Innovia LLC Company Overview 44

5.12.1 Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 44

5.13 Juvenis Ltd. Company Overview 45

5.13.1 Juvenis Ltd. Pipeline Products & Ongoing Clinical Trials Overview 45

5.14 Khorionyx SA Company Overview 46

5.14.1 Khorionyx SA Pipeline Products & Ongoing Clinical Trials Overview 46

5.15 L&C Bio Company Overview 47

5.15.1 L&C Bio Pipeline Products & Ongoing Clinical Trials Overview 47

5.16 Mentor Worldwide LLC Company Overview 48

5.16.1 Mentor Worldwide LLC Pipeline Products & Ongoing Clinical Trials Overview 48

5.17 Moma Therapeutics, Inc. Company Overview 49

5.17.1 Moma Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49

5.18 Mosaic Medical Technologies, Inc Company Overview 50

5.18.1 Mosaic Medical Technologies, Inc Pipeline Products & Ongoing Clinical Trials Overview 50

5.19 Oligo Medic, Inc. Company Overview 51

5.19.1 Oligo Medic, Inc. Pipeline Products & Ongoing Clinical Trials Overview 51

5.20 ORGEV Laboratories Company Overview 52

5.20.1 ORGEV Laboratories Pipeline Products & Ongoing Clinical Trials Overview 52

5.21 PetVivo Holdings Inc Company Overview 60

5.21.1 PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 60

5.22 Sekisui Medical Co Ltd Company Overview 62

5.22.1 Sekisui Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 62

5.23 Shanghai Haohai Biological Technology Co Ltd Company Overview 63

5.23.1 Shanghai Haohai Biological Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 63

5.24 Shin Poong PharmCo Ltd Company Overview 65

5.24.1 Shin Poong PharmCo Ltd Pipeline Products & Ongoing Clinical Trials Overview 65

5.25 Sinclair Pharma PLC Company Overview 66

5.25.1 Sinclair Pharma PLC Pipeline Products & Ongoing Clinical Trials Overview 66

5.26 Sofregen Medical Inc Company Overview 77

5.26.1 Sofregen Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 77

5.27 TEI Biosciences Inc Company Overview 78

5.27.1 TEI Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 78

5.28 University of California Santa Barbara Company Overview 79

5.28.1 University of California Santa Barbara Pipeline Products & Ongoing Clinical Trials Overview 79

6 Dermal Filler- Recent Developments 80

6.1 Jun 01, 2017: Suneva Medical Celebrates 10 Years of Steady Growth with Flagship Brand, Bellafill 80

6.2 May 09, 2017: FibroGen Reports First Quarter 2017 Financial Results 80

6.3 May 09, 2017: Oligo Medic Appoints Jerett Creed As CEO 81

6.4 May 05, 2017: Smith & Nephew 2017 First Quarter Trading Report 82

6.5 May 03, 2017: Anika Reports First Quarter 2017 Financial Results 84

6.6 Apr 24, 2017: Juvederm Vollure XC Dermal Filler -- Long Lasting FDA-Approved Treatment for Diminishing Nasolabial Folds Now Available at Contour Dermatology & Cosmetic Surgery Center 84

6.7 Apr 06, 2017: Galderma Presents Results From Phase 4 Clinical Study of Restylane Refyne at the 15th Aesthetic & Anti-aging Medicine Annual World Congress 85

6.8 Apr 06, 2017: Galderma Presents Results From Phase 4 Clinical Study of Restylane Defyne at the 15th Aesthetic & Anti-aging Medicine Annual World Congress 87

6.9 Apr 04, 2017: Merz Appoints Bob Rhatigan as President and Chief Executive Officer in North America 89

6.10 Mar 21, 2017: Sinclair Pharma Announces Preliminary results for the 12 and 18 months ended 31 December 2016 89

6.11 Mar 20, 2017: JUVEDERM VOLLURE XC Approved By U.S. FDA For Correction Of Facial Wrinkles And Folds In Adults Over The Age Of 21 90

6.12 Mar 01, 2017: FibroGen Reports Fiscal 2016 Financial Results 91

6.13 Feb 15, 2017: Anika Reports Fourth Quarter and Full Year 2016 Financial Results 92

6.14 Feb 15, 2017: Anika Therapeutics Reports 33% Revenue Growth in Third Quarter 2011 93

6.15 Feb 09, 2017: Smith & Nephew Fourth Quarter Trading and Full Year 2016 Results 95

6.16 Feb 09, 2017: Smith & Nephew: Directorate Change 100

6.17 Feb 01, 2017: CROMA-PHARMA opens 12th subsidiary in Germany 100

6.18 Jan 27, 2017: Allergan Launches Juvederm Volite-an Innovative Injectable Treatment Designed to Improve Skin Quality for up to 9 Months 100

6.19 Jan 17, 2017: Sinclair Pharma Announces Pre-Close Trading Update 101

6.20 Jan 12, 2017: Confirmation of CFO leaving Smith & Nephew 102

6.21 Dec 20, 2016: Appointment of Nestle Skin Health CEO ad interim 102

6.22 Dec 12, 2016: Galderma Announces FDA Approval of Restylane Refyne Dermal Filler for Treatment of "Laugh Lines" 103

6.23 Dec 12, 2016: Galderma Announces FDA Approval of Restylane Defyne Dermal Filler for Treatment of "Laugh Lines" 104

6.24 Nov 30, 2016: Graham Baker appointed Chief Financial Officer 105

6.25 Nov 21, 2016: Merz Continues Its Growth in Aesthetics and Neurotoxins 105

6.26 Nov 15, 2016: BTG: Interim results 107

6.27 Nov 08, 2016: FibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate Update 107

6.28 Nov 03, 2016: Smith & Nephew Third Quarter 2016 Trading Report 108

6.29 Oct 26, 2016: Anika Reports Third Quarter 2016 Financial Results 110

6.30 Oct 19, 2016: Facial Aesthetics First in Denver to Offer New Treatment to Help Patients Achieve "Goldilocks Lips" 111

6.31 Oct 18, 2016: JUVEDERM VOLBELLA XC Now Available To Doctors And Patients In The U.S. 111

6.32 Oct 10, 2016: Aesthetics Industry Veteran Pat Altavilla Joins Suneva Medical As Vice President Of Marketing 112

6.33 Oct 06, 2016: BTG: close period update 112

6.34 Sep 27, 2016: Orange County Business Council Study Showcases Economic Impact of Allergan on California Economy 113

6.35 Sep 23, 2016: Biologica Technologies launches Allofill injectable adipose filler at the annual gathering for the American Society of Plastic Surgeons 114

6.36 Sep 21, 2016: Sinclair Pharma: Second Interim Statement (Jan-Jun 2016) 114

6.37 Sep 01, 2016: Sinclair Pharma: Restructuring programme and Board change 116

6.38 Aug 08, 2016: FibroGen Reports Financial Results for the Second Quarter of 2016 116

6.39 Aug 04, 2016: Suneva Appoints Preston Romm To Chief Executive Officer And Fortifies Board Of Directors With Industry Leaders 117

6.40 Jul 28, 2016: Smith & Nephew Second Quarter Trading and First Half 2016 Results 118

6.41 Jul 27, 2016: BTG Announces Appointment of Non-executive Director 121

6.42 Jul 27, 2016: Anika Reports Second Quarter 2016 Financial Results 121

6.43 Jul 18, 2016: Trading update and notification of board changes �17.2m revenue in 1H calendar 2016 122

6.44 Jul 14, 2016: BTG: Annual General Meeting 123

6.45 Jul 11, 2016: CFO to leave Smith & Nephew in early 2017 124

6.46 Jun 16, 2016: Preston Romm Joins Suneva Medical As Chief Operating Officer 124

7 Appendix 125

7.1 Methodology 125

7.2 About GlobalData 128

7.3 Contact Us 128

7.4 Disclaimer 128


List Of Figure

1.2 List of Figures

Figure 1: Dermal Filler-Pipeline Products by Stage of Development 10

Figure 2: Dermal Filler-Pipeline Products by Territory 11

Figure 3: Dermal Filler-Pipeline Products by Regulatory Path 12

Figure 4: Dermal Filler-Pipeline Products by Estimated Approval Date 13

Figure 5: Dermal Filler-Ongoing Clinical Trials 14


List Of Table

1.1 List of Tables

Table 1: Dermal Filler-Pipeline Products by Stage of Development 10

Table 2: Dermal Filler-Pipeline Products by Territory 11

Table 3: Dermal Filler-Pipeline Products by Regulatory Path 12

Table 4: Dermal Filler-Pipeline Products by Estimated Approval Date 13

Table 5: Dermal Filler-Ongoing Clinical Trials 14

Table 6: Dermal Filler Companies-Pipeline Products by Stage of Development 15

Table 7: Dermal Filler-Pipeline Products by Stage of Development 17

Table 8: Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 19

Table 9: BioDermal Filler-Product Status 19

Table 10: BioDermal Filler-Product Description 19

Table 11: Allergan Inc Pipeline Products & Ongoing Clinical Trials Overview 20

Table 12: JUVEDERM Volbella-Product Status 20

Table 13: JUVEDERM Volbella-Product Description 20

Table 14: Juvederm Vollure XC-Product Status 21

Table 15: Juvederm Vollure XC-Product Description 21

Table 16: Juvederm VOLUMA XC-Product Status 21

Table 17: Juvederm VOLUMA XC-Product Description 22

Table 18: Allergan Inc-Ongoing Clinical Trials Overview 23

Table 19: Juvederm VOLUMA XC-A Multicenter, Single-blind, Randomized, Parallel-group, Controlled Study of the Safety and Effectiveness of Juvederm VOLUMA XC Injectable Gel for Correction of Temple Hollowing 24

Table 20: Juvederm VOLUMA XC-Clinical Study of Neuramis Volume Lidocaine to Evaluate the Efficacy and Safety for Temporary Restoring the Mid-face Volume 24

Table 21: Juvederm VOLUMA XC-Juvederm Voluma XC for the Treatment of Hypoplastic Chin 24

Table 22: Juvederm Vollure XC-A Safety and Efficacy Study of JUVEDERM VOLIFT with Lidocaine and Restylane for Nasolabial Folds in Chinese Adults 25

Table 23: Juvederm Vollure XC-Prospective Open Label Study to Evaluate the Effectiveness of Juvederm VOLIFT with Lidocaine for Treatment of Dynamic Radial Cheek Line Skin Depressions: BEAM 25

Table 24: Almirall Ltd Pipeline Products & Ongoing Clinical Trials Overview 26

Table 25: Hyaluronic Acid Facial Filler-Product Status 26

Table 26: Hyaluronic Acid Facial Filler-Product Description 26

Table 27: Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 27

Table 28: Next Generation ELEVESS Dermal Filler-Product Status 27

Table 29: Next Generation ELEVESS Dermal Filler-Product Description 27

Table 30: BioPolymer GmbH & Co. KG Pipeline Products & Ongoing Clinical Trials Overview 28

Table 31: Matridex-Product Status 28

Table 32: Matridex-Product Description 28

Table 33: Matridur-Product Status 29

Table 34: Matridur-Product Description 29

Table 35: Bioxis Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview 30

Table 36: Cytosial-Product Status 30

Table 37: Cytosial-Product Description 30

Table 38: Cytosmile-Product Status 31

Table 39: Cytosmile-Product Description 31

Table 40: Cytophil, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32

Table 41: Renu Soft Tissue Volumizing Filler-Aesthetic-Product Status 32

Table 42: Renu Soft Tissue Volumizing Filler-Aesthetic-Product Description 32

Table 43: Dermele Skin Care, LLC Pipeline Products & Ongoing Clinical Trials Overview 33

Table 44: Gold Nanoparticle Dermal Filler-Product Status 33

Table 45: Gold Nanoparticle Dermal Filler-Product Description 33

Table 46: EternoGen, LLC Pipeline Products & Ongoing Clinical Trials Overview 34

Table 47: Collagen Scaffold-Aesthetic Procedures-Product Status 34

Table 48: Collagen Scaffold-Aesthetic Procedures-Product Description 34

Table 49: FibroGen Inc Pipeline Products & Ongoing Clinical Trials Overview 35

Table 50: FG-5030-Product Status 35

Table 51: FG-5030-Product Description 35

Table 52: Galderma SA Pipeline Products & Ongoing Clinical Trials Overview 36

Table 53: Restylane Lidocaine-Product Status 36

Table 54: Restylane Lidocaine-Product Description 36

Table 55: Restylane Lyft-Hand Rejuvenation-Product Status 37

Table 56: Restylane Lyft-Hand Rejuvenation-Product Description 37

Table 57: Restylane Perlane-Product Status 37

Table 58: Restylane Perlane-Product Description 38

Table 59: Restylane Skinboosters Vital-Product Status 38

Table 60: Restylane Skinboosters Vital-Product Description 38

Table 61: Galderma SA-Ongoing Clinical Trials Overview 39

Table 62: Restylane Perlane-A Randomized, Multi-center, Evaluator-blinded, No-treatment Controlled Study to Evaluate the Efficacy and Safety of Restylane Perlane Lidocaine for Correction of Midface Volume Deficit And/Or Midface Contour Deficiency 40

Table 63: Restylane Perlane-A Randomized, Multi-center, Subject and Evaluator-blinded Study Comparing the Pain and the Safety Profile Associate with Correction of Moderate to Severe Nasolabial Folds Using Restylane Perlane Lidocaine Compared to Restylane Perlane 40

Table 64: Restylane Perlane-An Open, Evaluator-blinded, Non-comparative, Multi-center Study to Assess the Safety and Efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine for Facial Augmentation in Asian Population 40

Table 65: Restylane Lidocaine-A Multicenter, Active-controlled, Randomized, Evaluator and Subject Blinded, Split-face, Comparative, Non-inferiority and Confirmatory Clinical Study of the Efficacy and Safety Between YYD701-2 and Restylane Perlane Lidocaine for Temporary Correction of Moderate to Severe Nasolabial Folds 41

Table 66: Restylane Lidocaine-A Randomized, Evaluator-blind Comparative Study to Evaluate Performance and Safety of Restylane Lidocaine and No-treatment Control for Treatment of Depressed Facial Acne Scars 41

Table 67: Restylane Lidocaine-A Randomized, Multi-center, Subject and Evaluator-blinded Study Comparing Pain and Safety Profile Associated with Correction of Moderate to Severe Nasolabial Folds Using Restylane with and without Addition of 0.3% Lidocaine Hydrochloride 41

Table 68: Restylane Lidocaine-A Randomized, Multi-center, Subject and Evaluator-blinded Study Comparing the Pain and the Safety Profile Associate with Correction of Moderate to Severe Nasolabial Folds Using Restylane Perlane Lidocaine Compared to Restylane Perlane 42

Table 69: Restylane Lidocaine-An Open, Evaluator-blinded, Non-comparative, Multi-center Study to Assess the Safety and Efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine for Facial Augmentation in Asian Population 42

Table 70: Restylane Skinboosters Vital-A Randomized, Multi-center, Evaluator-blinded, Split-hand, no Treatment-controlled Study to Evaluate the Safety and Efficacy of Restylane Vital for Skin Rejuvenation of the Dorsal Hands in Chinese Subjects 43

Table 71: Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 44

Table 72: Wrinkle Filler-Product Status 44

Table 73: Wrinkle Filler-Product Description 44

Table 74: Juvenis Ltd. Pipeline Products & Ongoing Clinical Trials Overview 45

Table 75: Tenergel-Product Status 45

Table 76: Tenergel-Product Description 45

Table 77: Khorionyx SA Pipeline Products & Ongoing Clinical Trials Overview 46

Table 78: Autologous Globin Dermal Filler-Product Status 46

Table 79: Autologous Globin Dermal Filler-Product Description 46

Table 80: L&C Bio Pipeline Products & Ongoing Clinical Trials Overview 47

Table 81: Micronized Acellular Dermal Filler-Product Status 47

Table 82: Micronized Acellular Dermal Filler-Product Description 47

Table 83: Mentor Worldwide LLC Pipeline Products & Ongoing Clinical Trials Overview 48

Table 84: Prevelle Shape-Product Status 48

Table 85: Prevelle Shape-Product Description 48

Table 86: Moma Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49

Table 87: Restogel-131-Product Status 49

Table 88: Restogel-131-Product Description 49

Table 89: Mosaic Medical Technologies, Inc Pipeline Products & Ongoing Clinical Trials Overview 50

Table 90: Dermal Filler-Product Status 50

Table 91: Dermal Filler-Product Description 50

Table 92: Oligo Medic, Inc. Pipeline Products & Ongoing Clinical Trials Overview 51

Table 93: AntaRep-Product Status 51

Table 94: AntaRep-Product Description 51

Table 95: ORGEV Laboratories Pipeline Products & Ongoing Clinical Trials Overview 52

Table 96: Macdermol 18-Product Status 52

Table 97: Macdermol 18-Product Description 53

Table 98: Macdermol 21-Product Status 53

Table 99: Macdermol 21-Product Description 53

Table 100: Macdermol 24-Product Status 54

Table 101: Macdermol 24-Product Description 54

Table 102: Macdermol 30-Product Status 54

Table 103: Macdermol 30-Product Description 55

Table 104: Macdermol Bio Lift-Product Status 55

Table 105: Macdermol Bio Lift-Product Description 55

Table 106: Macdermol Bio Revitalization-Product Status 56

Table 107: Macdermol Bio Revitalization-Product Description 56

Table 108: Macdermol Hydro-Product Status 56

Table 109: Macdermol Hydro-Product Description 57

Table 110: Macdermol Lips-Product Status 57

Table 111: Macdermol Lips-Product Description 57

Table 112: MacDermol R-Product Status 58

Table 113: MacDermol R-Product Description 58

Table 114: MacDermol S-Product Status 58

Table 115: MacDermol S-Product Description 59

Table 116: Macdermol Volume-Product Status 59

Table 117: Macdermol Volume-Product Description 59

Table 118: PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 60

Table 119: Dermal Filler-Product Status 60

Table 120: Dermal Filler-Product Description 60

Table 121: Dermal Filler-Lip-Product Status 61

Table 122: Dermal Filler-Lip-Product Description 61

Table 123: Sekisui Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 62

Table 124: NADGL-Product Status 62

Table 125: NADGL-Product Description 62

Table 126: Shanghai Haohai Biological Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 63

Table 127: QST Gel-Product Status 63

Table 128: QST Gel-Product Description 63

Table 129: Third Generation Matrifill-Product Status 64

Table 130: Third Generation Matrifill-Product Description 64

Table 131: Shin Poong PharmCo Ltd Pipeline Products & Ongoing Clinical Trials Overview 65

Table 132: Dermal Filler-Product Status 65

Table 133: Dermal Filler-Product Description 65

Table 134: Sinclair Pharma PLC Pipeline Products & Ongoing Clinical Trials Overview 66

Table 135: Atlean-Product Status 67

Table 136: Atlean-Product Description 67

Table 137: Ellanse Hands-M-Product Status 68

Table 138: Ellanse Hands-M-Product Description 68

Table 139: Ellanse Hands-S-Product Status 69

Table 140: Ellanse Hands-S-Product Description 69

Table 141: Ellans� Lidocaine-Product Status 70

Table 142: Ellans� Lidocaine-Product Description 70

Table 143: Ellans�-E-Product Status 71

Table 144: Ellans�-E-Product Description 71

Table 145: Ellans�-L-Product Status 72

Table 146: Ellans�-L-Product Description 72

Table 147: Ellans�-M-Product Status 73

Table 148: Ellans�-M-Product Description 73

Table 149: Ellans�-S-Product Status 74

Table 150: Ellans�-S-Product Description 74

Table 151: Perfectha G-Product Status 75

Table 152: Perfectha G-Product Description 75

Table 153: Perfectha Lidocaine-Product Status 75

Table 154: Perfectha Lidocaine-Product Description 76

Table 155: Sofregen Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 77

Table 156: Silk Protein-Tissue/Dermal Filler-Product Status 77

Table 157: Silk Protein-Tissue/Dermal Filler-Product Description 77

Table 158: TEI Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 78

Table 159: Injectable Dermal Filler-Product Status 78

Table 160: Injectable Dermal Filler-Product Description 78

Table 161: University of California Santa Barbara Pipeline Products & Ongoing Clinical Trials Overview 79

Table 162: Needle Free Injector-Product Status 79

Table 163: Needle Free Injector-Product Description 79

Table 164: Glossary 127

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Aeon Astron Corporation, Allergan Inc, Almirall Ltd, Anika Therapeutics Inc, BioPolymer GmbH & Co. KG, Bioxis Pharmaceuticals, Cytophil, Inc., Dermele Skin Care, LLC, EternoGen, LLC, FibroGen Inc, Galderma SA, Innovia LLC, Juvenis Ltd., Khorionyx SA, L&C Bio, Mentor Worldwide LLC, Moma Therapeutics, Inc., Mosaic Medical Technologies, Inc, Oligo Medic, Inc., ORGEV Laboratories, PetVivo Holdings Inc, Sekisui Medical Co Ltd, Shanghai Haohai Biological Technology Co Ltd, Shin Poong PharmCo Ltd, Sinclair Pharma PLC, Sofregen Medical Inc, TEI Biosciences Inc, University of California Santa Barbara

Company Profile

Company Profile Title

Dermal Filler-Medical Devices Pipeline Assessment, 2017

Summary

GlobalData's Medical Devices sector report, "Dermal Filler-Medical Devices Pipeline Assessment, 2017" provides an overview of Dermal Filler currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dermal Filler pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

Extensive coverage of the Dermal Filler under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Dermal Filler and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

Reasons to buy

The report enables you to-

Formulate significant competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Dermal Filler under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the product's current stage of development, territory and estimated launch date

READ MORE

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 8

2 Introduction 9

2.1 Dermal Filler Overview 9

3 Products under Development 10

3.1 Dermal Filler-Pipeline Products by Stage of Development 10

3.2 Dermal Filler-Pipeline Products by Territory 11

3.3 Dermal Filler-Pipeline Products by Regulatory Path 12

3.4 Dermal Filler-Pipeline Products by Estimated Approval Date 13

3.5 Dermal Filler-Ongoing Clinical Trials 14

4 Dermal Filler-Pipeline Products under Development by Companies 15

4.1 Dermal Filler Companies-Pipeline Products by Stage of Development 15

4.2 Dermal Filler-Pipeline Products by Stage of Development 17

5 Dermal Filler Companies and Product Overview 19

5.1 Aeon Astron Corporation Company Overview 19

5.1.1 Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 19

5.2 Allergan Inc Company Overview 20

5.2.1 Allergan Inc Pipeline Products & Ongoing Clinical Trials Overview 20

5.3 Almirall Ltd Company Overview 26

5.3.1 Almirall Ltd Pipeline Products & Ongoing Clinical Trials Overview 26

5.4 Anika Therapeutics Inc Company Overview 27

5.4.1 Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 27

5.5 BioPolymer GmbH & Co. KG Company Overview 28

5.5.1 BioPolymer GmbH & Co. KG Pipeline Products & Ongoing Clinical Trials Overview 28

5.6 Bioxis Pharmaceuticals Company Overview 30

5.6.1 Bioxis Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview 30

5.7 Cytophil, Inc. Company Overview 32

5.7.1 Cytophil, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32

5.8 Dermele Skin Care, LLC Company Overview 33

5.8.1 Dermele Skin Care, LLC Pipeline Products & Ongoing Clinical Trials Overview 33

5.9 EternoGen, LLC Company Overview 34

5.9.1 EternoGen, LLC Pipeline Products & Ongoing Clinical Trials Overview 34

5.10 FibroGen Inc Company Overview 35

5.10.1 FibroGen Inc Pipeline Products & Ongoing Clinical Trials Overview 35

5.11 Galderma SA Company Overview 36

5.11.1 Galderma SA Pipeline Products & Ongoing Clinical Trials Overview 36

5.12 Innovia LLC Company Overview 44

5.12.1 Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 44

5.13 Juvenis Ltd. Company Overview 45

5.13.1 Juvenis Ltd. Pipeline Products & Ongoing Clinical Trials Overview 45

5.14 Khorionyx SA Company Overview 46

5.14.1 Khorionyx SA Pipeline Products & Ongoing Clinical Trials Overview 46

5.15 L&C Bio Company Overview 47

5.15.1 L&C Bio Pipeline Products & Ongoing Clinical Trials Overview 47

5.16 Mentor Worldwide LLC Company Overview 48

5.16.1 Mentor Worldwide LLC Pipeline Products & Ongoing Clinical Trials Overview 48

5.17 Moma Therapeutics, Inc. Company Overview 49

5.17.1 Moma Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49

5.18 Mosaic Medical Technologies, Inc Company Overview 50

5.18.1 Mosaic Medical Technologies, Inc Pipeline Products & Ongoing Clinical Trials Overview 50

5.19 Oligo Medic, Inc. Company Overview 51

5.19.1 Oligo Medic, Inc. Pipeline Products & Ongoing Clinical Trials Overview 51

5.20 ORGEV Laboratories Company Overview 52

5.20.1 ORGEV Laboratories Pipeline Products & Ongoing Clinical Trials Overview 52

5.21 PetVivo Holdings Inc Company Overview 60

5.21.1 PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 60

5.22 Sekisui Medical Co Ltd Company Overview 62

5.22.1 Sekisui Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 62

5.23 Shanghai Haohai Biological Technology Co Ltd Company Overview 63

5.23.1 Shanghai Haohai Biological Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 63

5.24 Shin Poong PharmCo Ltd Company Overview 65

5.24.1 Shin Poong PharmCo Ltd Pipeline Products & Ongoing Clinical Trials Overview 65

5.25 Sinclair Pharma PLC Company Overview 66

5.25.1 Sinclair Pharma PLC Pipeline Products & Ongoing Clinical Trials Overview 66

5.26 Sofregen Medical Inc Company Overview 77

5.26.1 Sofregen Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 77

5.27 TEI Biosciences Inc Company Overview 78

5.27.1 TEI Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 78

5.28 University of California Santa Barbara Company Overview 79

5.28.1 University of California Santa Barbara Pipeline Products & Ongoing Clinical Trials Overview 79

6 Dermal Filler- Recent Developments 80

6.1 Jun 01, 2017: Suneva Medical Celebrates 10 Years of Steady Growth with Flagship Brand, Bellafill 80

6.2 May 09, 2017: FibroGen Reports First Quarter 2017 Financial Results 80

6.3 May 09, 2017: Oligo Medic Appoints Jerett Creed As CEO 81

6.4 May 05, 2017: Smith & Nephew 2017 First Quarter Trading Report 82

6.5 May 03, 2017: Anika Reports First Quarter 2017 Financial Results 84

6.6 Apr 24, 2017: Juvederm Vollure XC Dermal Filler -- Long Lasting FDA-Approved Treatment for Diminishing Nasolabial Folds Now Available at Contour Dermatology & Cosmetic Surgery Center 84

6.7 Apr 06, 2017: Galderma Presents Results From Phase 4 Clinical Study of Restylane Refyne at the 15th Aesthetic & Anti-aging Medicine Annual World Congress 85

6.8 Apr 06, 2017: Galderma Presents Results From Phase 4 Clinical Study of Restylane Defyne at the 15th Aesthetic & Anti-aging Medicine Annual World Congress 87

6.9 Apr 04, 2017: Merz Appoints Bob Rhatigan as President and Chief Executive Officer in North America 89

6.10 Mar 21, 2017: Sinclair Pharma Announces Preliminary results for the 12 and 18 months ended 31 December 2016 89

6.11 Mar 20, 2017: JUVEDERM VOLLURE XC Approved By U.S. FDA For Correction Of Facial Wrinkles And Folds In Adults Over The Age Of 21 90

6.12 Mar 01, 2017: FibroGen Reports Fiscal 2016 Financial Results 91

6.13 Feb 15, 2017: Anika Reports Fourth Quarter and Full Year 2016 Financial Results 92

6.14 Feb 15, 2017: Anika Therapeutics Reports 33% Revenue Growth in Third Quarter 2011 93

6.15 Feb 09, 2017: Smith & Nephew Fourth Quarter Trading and Full Year 2016 Results 95

6.16 Feb 09, 2017: Smith & Nephew: Directorate Change 100

6.17 Feb 01, 2017: CROMA-PHARMA opens 12th subsidiary in Germany 100

6.18 Jan 27, 2017: Allergan Launches Juvederm Volite-an Innovative Injectable Treatment Designed to Improve Skin Quality for up to 9 Months 100

6.19 Jan 17, 2017: Sinclair Pharma Announces Pre-Close Trading Update 101

6.20 Jan 12, 2017: Confirmation of CFO leaving Smith & Nephew 102

6.21 Dec 20, 2016: Appointment of Nestle Skin Health CEO ad interim 102

6.22 Dec 12, 2016: Galderma Announces FDA Approval of Restylane Refyne Dermal Filler for Treatment of "Laugh Lines" 103

6.23 Dec 12, 2016: Galderma Announces FDA Approval of Restylane Defyne Dermal Filler for Treatment of "Laugh Lines" 104

6.24 Nov 30, 2016: Graham Baker appointed Chief Financial Officer 105

6.25 Nov 21, 2016: Merz Continues Its Growth in Aesthetics and Neurotoxins 105

6.26 Nov 15, 2016: BTG: Interim results 107

6.27 Nov 08, 2016: FibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate Update 107

6.28 Nov 03, 2016: Smith & Nephew Third Quarter 2016 Trading Report 108

6.29 Oct 26, 2016: Anika Reports Third Quarter 2016 Financial Results 110

6.30 Oct 19, 2016: Facial Aesthetics First in Denver to Offer New Treatment to Help Patients Achieve "Goldilocks Lips" 111

6.31 Oct 18, 2016: JUVEDERM VOLBELLA XC Now Available To Doctors And Patients In The U.S. 111

6.32 Oct 10, 2016: Aesthetics Industry Veteran Pat Altavilla Joins Suneva Medical As Vice President Of Marketing 112

6.33 Oct 06, 2016: BTG: close period update 112

6.34 Sep 27, 2016: Orange County Business Council Study Showcases Economic Impact of Allergan on California Economy 113

6.35 Sep 23, 2016: Biologica Technologies launches Allofill injectable adipose filler at the annual gathering for the American Society of Plastic Surgeons 114

6.36 Sep 21, 2016: Sinclair Pharma: Second Interim Statement (Jan-Jun 2016) 114

6.37 Sep 01, 2016: Sinclair Pharma: Restructuring programme and Board change 116

6.38 Aug 08, 2016: FibroGen Reports Financial Results for the Second Quarter of 2016 116

6.39 Aug 04, 2016: Suneva Appoints Preston Romm To Chief Executive Officer And Fortifies Board Of Directors With Industry Leaders 117

6.40 Jul 28, 2016: Smith & Nephew Second Quarter Trading and First Half 2016 Results 118

6.41 Jul 27, 2016: BTG Announces Appointment of Non-executive Director 121

6.42 Jul 27, 2016: Anika Reports Second Quarter 2016 Financial Results 121

6.43 Jul 18, 2016: Trading update and notification of board changes �17.2m revenue in 1H calendar 2016 122

6.44 Jul 14, 2016: BTG: Annual General Meeting 123

6.45 Jul 11, 2016: CFO to leave Smith & Nephew in early 2017 124

6.46 Jun 16, 2016: Preston Romm Joins Suneva Medical As Chief Operating Officer 124

7 Appendix 125

7.1 Methodology 125

7.2 About GlobalData 128

7.3 Contact Us 128

7.4 Disclaimer 128


List Of Figure

1.2 List of Figures

Figure 1: Dermal Filler-Pipeline Products by Stage of Development 10

Figure 2: Dermal Filler-Pipeline Products by Territory 11

Figure 3: Dermal Filler-Pipeline Products by Regulatory Path 12

Figure 4: Dermal Filler-Pipeline Products by Estimated Approval Date 13

Figure 5: Dermal Filler-Ongoing Clinical Trials 14


List Of Table

1.1 List of Tables

Table 1: Dermal Filler-Pipeline Products by Stage of Development 10

Table 2: Dermal Filler-Pipeline Products by Territory 11

Table 3: Dermal Filler-Pipeline Products by Regulatory Path 12

Table 4: Dermal Filler-Pipeline Products by Estimated Approval Date 13

Table 5: Dermal Filler-Ongoing Clinical Trials 14

Table 6: Dermal Filler Companies-Pipeline Products by Stage of Development 15

Table 7: Dermal Filler-Pipeline Products by Stage of Development 17

Table 8: Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 19

Table 9: BioDermal Filler-Product Status 19

Table 10: BioDermal Filler-Product Description 19

Table 11: Allergan Inc Pipeline Products & Ongoing Clinical Trials Overview 20

Table 12: JUVEDERM Volbella-Product Status 20

Table 13: JUVEDERM Volbella-Product Description 20

Table 14: Juvederm Vollure XC-Product Status 21

Table 15: Juvederm Vollure XC-Product Description 21

Table 16: Juvederm VOLUMA XC-Product Status 21

Table 17: Juvederm VOLUMA XC-Product Description 22

Table 18: Allergan Inc-Ongoing Clinical Trials Overview 23

Table 19: Juvederm VOLUMA XC-A Multicenter, Single-blind, Randomized, Parallel-group, Controlled Study of the Safety and Effectiveness of Juvederm VOLUMA XC Injectable Gel for Correction of Temple Hollowing 24

Table 20: Juvederm VOLUMA XC-Clinical Study of Neuramis Volume Lidocaine to Evaluate the Efficacy and Safety for Temporary Restoring the Mid-face Volume 24

Table 21: Juvederm VOLUMA XC-Juvederm Voluma XC for the Treatment of Hypoplastic Chin 24

Table 22: Juvederm Vollure XC-A Safety and Efficacy Study of JUVEDERM VOLIFT with Lidocaine and Restylane for Nasolabial Folds in Chinese Adults 25

Table 23: Juvederm Vollure XC-Prospective Open Label Study to Evaluate the Effectiveness of Juvederm VOLIFT with Lidocaine for Treatment of Dynamic Radial Cheek Line Skin Depressions: BEAM 25

Table 24: Almirall Ltd Pipeline Products & Ongoing Clinical Trials Overview 26

Table 25: Hyaluronic Acid Facial Filler-Product Status 26

Table 26: Hyaluronic Acid Facial Filler-Product Description 26

Table 27: Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 27

Table 28: Next Generation ELEVESS Dermal Filler-Product Status 27

Table 29: Next Generation ELEVESS Dermal Filler-Product Description 27

Table 30: BioPolymer GmbH & Co. KG Pipeline Products & Ongoing Clinical Trials Overview 28

Table 31: Matridex-Product Status 28

Table 32: Matridex-Product Description 28

Table 33: Matridur-Product Status 29

Table 34: Matridur-Product Description 29

Table 35: Bioxis Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview 30

Table 36: Cytosial-Product Status 30

Table 37: Cytosial-Product Description 30

Table 38: Cytosmile-Product Status 31

Table 39: Cytosmile-Product Description 31

Table 40: Cytophil, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32

Table 41: Renu Soft Tissue Volumizing Filler-Aesthetic-Product Status 32

Table 42: Renu Soft Tissue Volumizing Filler-Aesthetic-Product Description 32

Table 43: Dermele Skin Care, LLC Pipeline Products & Ongoing Clinical Trials Overview 33

Table 44: Gold Nanoparticle Dermal Filler-Product Status 33

Table 45: Gold Nanoparticle Dermal Filler-Product Description 33

Table 46: EternoGen, LLC Pipeline Products & Ongoing Clinical Trials Overview 34

Table 47: Collagen Scaffold-Aesthetic Procedures-Product Status 34

Table 48: Collagen Scaffold-Aesthetic Procedures-Product Description 34

Table 49: FibroGen Inc Pipeline Products & Ongoing Clinical Trials Overview 35

Table 50: FG-5030-Product Status 35

Table 51: FG-5030-Product Description 35

Table 52: Galderma SA Pipeline Products & Ongoing Clinical Trials Overview 36

Table 53: Restylane Lidocaine-Product Status 36

Table 54: Restylane Lidocaine-Product Description 36

Table 55: Restylane Lyft-Hand Rejuvenation-Product Status 37

Table 56: Restylane Lyft-Hand Rejuvenation-Product Description 37

Table 57: Restylane Perlane-Product Status 37

Table 58: Restylane Perlane-Product Description 38

Table 59: Restylane Skinboosters Vital-Product Status 38

Table 60: Restylane Skinboosters Vital-Product Description 38

Table 61: Galderma SA-Ongoing Clinical Trials Overview 39

Table 62: Restylane Perlane-A Randomized, Multi-center, Evaluator-blinded, No-treatment Controlled Study to Evaluate the Efficacy and Safety of Restylane Perlane Lidocaine for Correction of Midface Volume Deficit And/Or Midface Contour Deficiency 40

Table 63: Restylane Perlane-A Randomized, Multi-center, Subject and Evaluator-blinded Study Comparing the Pain and the Safety Profile Associate with Correction of Moderate to Severe Nasolabial Folds Using Restylane Perlane Lidocaine Compared to Restylane Perlane 40

Table 64: Restylane Perlane-An Open, Evaluator-blinded, Non-comparative, Multi-center Study to Assess the Safety and Efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine for Facial Augmentation in Asian Population 40

Table 65: Restylane Lidocaine-A Multicenter, Active-controlled, Randomized, Evaluator and Subject Blinded, Split-face, Comparative, Non-inferiority and Confirmatory Clinical Study of the Efficacy and Safety Between YYD701-2 and Restylane Perlane Lidocaine for Temporary Correction of Moderate to Severe Nasolabial Folds 41

Table 66: Restylane Lidocaine-A Randomized, Evaluator-blind Comparative Study to Evaluate Performance and Safety of Restylane Lidocaine and No-treatment Control for Treatment of Depressed Facial Acne Scars 41

Table 67: Restylane Lidocaine-A Randomized, Multi-center, Subject and Evaluator-blinded Study Comparing Pain and Safety Profile Associated with Correction of Moderate to Severe Nasolabial Folds Using Restylane with and without Addition of 0.3% Lidocaine Hydrochloride 41

Table 68: Restylane Lidocaine-A Randomized, Multi-center, Subject and Evaluator-blinded Study Comparing the Pain and the Safety Profile Associate with Correction of Moderate to Severe Nasolabial Folds Using Restylane Perlane Lidocaine Compared to Restylane Perlane 42

Table 69: Restylane Lidocaine-An Open, Evaluator-blinded, Non-comparative, Multi-center Study to Assess the Safety and Efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine for Facial Augmentation in Asian Population 42

Table 70: Restylane Skinboosters Vital-A Randomized, Multi-center, Evaluator-blinded, Split-hand, no Treatment-controlled Study to Evaluate the Safety and Efficacy of Restylane Vital for Skin Rejuvenation of the Dorsal Hands in Chinese Subjects 43

Table 71: Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 44

Table 72: Wrinkle Filler-Product Status 44

Table 73: Wrinkle Filler-Product Description 44

Table 74: Juvenis Ltd. Pipeline Products & Ongoing Clinical Trials Overview 45

Table 75: Tenergel-Product Status 45

Table 76: Tenergel-Product Description 45

Table 77: Khorionyx SA Pipeline Products & Ongoing Clinical Trials Overview 46

Table 78: Autologous Globin Dermal Filler-Product Status 46

Table 79: Autologous Globin Dermal Filler-Product Description 46

Table 80: L&C Bio Pipeline Products & Ongoing Clinical Trials Overview 47

Table 81: Micronized Acellular Dermal Filler-Product Status 47

Table 82: Micronized Acellular Dermal Filler-Product Description 47

Table 83: Mentor Worldwide LLC Pipeline Products & Ongoing Clinical Trials Overview 48

Table 84: Prevelle Shape-Product Status 48

Table 85: Prevelle Shape-Product Description 48

Table 86: Moma Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49

Table 87: Restogel-131-Product Status 49

Table 88: Restogel-131-Product Description 49

Table 89: Mosaic Medical Technologies, Inc Pipeline Products & Ongoing Clinical Trials Overview 50

Table 90: Dermal Filler-Product Status 50

Table 91: Dermal Filler-Product Description 50

Table 92: Oligo Medic, Inc. Pipeline Products & Ongoing Clinical Trials Overview 51

Table 93: AntaRep-Product Status 51

Table 94: AntaRep-Product Description 51

Table 95: ORGEV Laboratories Pipeline Products & Ongoing Clinical Trials Overview 52

Table 96: Macdermol 18-Product Status 52

Table 97: Macdermol 18-Product Description 53

Table 98: Macdermol 21-Product Status 53

Table 99: Macdermol 21-Product Description 53

Table 100: Macdermol 24-Product Status 54

Table 101: Macdermol 24-Product Description 54

Table 102: Macdermol 30-Product Status 54

Table 103: Macdermol 30-Product Description 55

Table 104: Macdermol Bio Lift-Product Status 55

Table 105: Macdermol Bio Lift-Product Description 55

Table 106: Macdermol Bio Revitalization-Product Status 56

Table 107: Macdermol Bio Revitalization-Product Description 56

Table 108: Macdermol Hydro-Product Status 56

Table 109: Macdermol Hydro-Product Description 57

Table 110: Macdermol Lips-Product Status 57

Table 111: Macdermol Lips-Product Description 57

Table 112: MacDermol R-Product Status 58

Table 113: MacDermol R-Product Description 58

Table 114: MacDermol S-Product Status 58

Table 115: MacDermol S-Product Description 59

Table 116: Macdermol Volume-Product Status 59

Table 117: Macdermol Volume-Product Description 59

Table 118: PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 60

Table 119: Dermal Filler-Product Status 60

Table 120: Dermal Filler-Product Description 60

Table 121: Dermal Filler-Lip-Product Status 61

Table 122: Dermal Filler-Lip-Product Description 61

Table 123: Sekisui Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 62

Table 124: NADGL-Product Status 62

Table 125: NADGL-Product Description 62

Table 126: Shanghai Haohai Biological Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 63

Table 127: QST Gel-Product Status 63

Table 128: QST Gel-Product Description 63

Table 129: Third Generation Matrifill-Product Status 64

Table 130: Third Generation Matrifill-Product Description 64

Table 131: Shin Poong PharmCo Ltd Pipeline Products & Ongoing Clinical Trials Overview 65

Table 132: Dermal Filler-Product Status 65

Table 133: Dermal Filler-Product Description 65

Table 134: Sinclair Pharma PLC Pipeline Products & Ongoing Clinical Trials Overview 66

Table 135: Atlean-Product Status 67

Table 136: Atlean-Product Description 67

Table 137: Ellanse Hands-M-Product Status 68

Table 138: Ellanse Hands-M-Product Description 68

Table 139: Ellanse Hands-S-Product Status 69

Table 140: Ellanse Hands-S-Product Description 69

Table 141: Ellans� Lidocaine-Product Status 70

Table 142: Ellans� Lidocaine-Product Description 70

Table 143: Ellans�-E-Product Status 71

Table 144: Ellans�-E-Product Description 71

Table 145: Ellans�-L-Product Status 72

Table 146: Ellans�-L-Product Description 72

Table 147: Ellans�-M-Product Status 73

Table 148: Ellans�-M-Product Description 73

Table 149: Ellans�-S-Product Status 74

Table 150: Ellans�-S-Product Description 74

Table 151: Perfectha G-Product Status 75

Table 152: Perfectha G-Product Description 75

Table 153: Perfectha Lidocaine-Product Status 75

Table 154: Perfectha Lidocaine-Product Description 76

Table 155: Sofregen Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 77

Table 156: Silk Protein-Tissue/Dermal Filler-Product Status 77

Table 157: Silk Protein-Tissue/Dermal Filler-Product Description 77

Table 158: TEI Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 78

Table 159: Injectable Dermal Filler-Product Status 78

Table 160: Injectable Dermal Filler-Product Description 78

Table 161: University of California Santa Barbara Pipeline Products & Ongoing Clinical Trials Overview 79

Table 162: Needle Free Injector-Product Status 79

Table 163: Needle Free Injector-Product Description 79

Table 164: Glossary 127

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Aeon Astron Corporation, Allergan Inc, Almirall Ltd, Anika Therapeutics Inc, BioPolymer GmbH & Co. KG, Bioxis Pharmaceuticals, Cytophil, Inc., Dermele Skin Care, LLC, EternoGen, LLC, FibroGen Inc, Galderma SA, Innovia LLC, Juvenis Ltd., Khorionyx SA, L&C Bio, Mentor Worldwide LLC, Moma Therapeutics, Inc., Mosaic Medical Technologies, Inc, Oligo Medic, Inc., ORGEV Laboratories, PetVivo Holdings Inc, Sekisui Medical Co Ltd, Shanghai Haohai Biological Technology Co Ltd, Shin Poong PharmCo Ltd, Sinclair Pharma PLC, Sofregen Medical Inc, TEI Biosciences Inc, University of California Santa Barbara